CompletedPhase 2NCT00600054
Phase 2 Study of Nimotuzumab in Pediatric Recurrent Diffuse Intrinsic Pontine Glioma
Studying Diffuse intrinsic pontine glioma
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- YM BioSciences
- Principal Investigator
- Eric Bouffet, MDThe Hospital for Sick Children
- Intervention
- nimotuzumab (anti EGFR humanized monoclonal antibody)(biological)
- Enrollment
- 44 enrolled
- Eligibility
- 3-18 years · All sexes
- Timeline
- 2007 – 2010
Study locations (13)
- Children's Hospital/University of Colorado, Denver, Colorado, United States
- Children's National Medical Center, Washington D.C., District of Columbia, United States
- University of Florida Shands Cancer Center, Gainesville, Florida, United States
- Children's Memorial Hospital, Chicago, Illinois, United States
- The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins, Baltimore, Maryland, United States
- NYU Medical Center, Hassenfeld Clinic, New York, New York, United States
- Memorial Sloan-Kettering Cancer Center, New York, New York, United States
- University of Rochester Medical Center, Strong Memorial Hospital, Rochester, New York, United States
- Vanderbilt University Medical Center, Nashville, Tennessee, United States
- The University of Texas/M.D. Anderson Cancer Center, Houston, Texas, United States
- Alberta Children's Hospital, Calgary, Alberta, Canada
- The Hospital For Sick Children, Toronto, Ontario, Canada
- The Chaim Sheba Medical Center, Tel Litwinsky, Tel-Hashomer, Israel
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT00600054 on ClinicalTrials.govOther trials for Diffuse intrinsic pontine glioma
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE1NCT07076498Engineered HSV-1 M032 for the Treatment of Children and Adults With Newly Diagnosed Diffuse Midline Glioma After Standard of Care RadiationM.D. Anderson Cancer Center
- RECRUITINGPHASE1, PHASE2NCT07501156H3K27M-specific Immune Effector Cells Targeting DMG/DIPGShenzhen Geno-Immune Medical Institute
- RECRUITINGPHASE2NCT06838676ACT001 for the Treatment of Diffuse Intrinsic Pontine Gliomas and H3K27-altered High Grade GliomasNationwide Children's Hospital
- RECRUITINGPHASE1NCT06305910CD200AR-L and Allogeneic Tumor Lysate Vaccine Immunotherapy for Recurrent HGG and Newly Diagnosed DMG/DIPG in Children and Young AdultsOX2 Therapeutics
- RECRUITINGPHASE1NCT06221553Safety and Efficacy of Loco-regional B7H3 IL-7Ra CAR T Cell in DIPGChulalongkorn University
- RECRUITINGPHASE1NCT05544526CAR T Cells to Target GD2 for DMGUniversity College, London
- RECRUITINGPHASE1NCT05762419FUS Etoposide for DMGColumbia University
- ACTIVE NOT RECRUITINGPHASE1NCT05768880Study of B7-H3, EGFR806, HER2, And IL13-Zetakine (Quad) CAR T Cell Locoregional Immunotherapy For Pediatric Diffuse Intrinsic Pontine Glioma, Diffuse Midline Glioma, And Recurrent Or Refractory Central Nervous System TumorsSeattle Children's Hospital